Table S1: Treatment ongoing at time of CTC determination

|  |  |
| --- | --- |
| **Treatment** | **All patients (n=37)** |
| Abiraterone | 26 (70)  11 (30) |
| Enzalutamide |
| **Treatment Line** |  |
| * 1st | 31 (84) |
| * 2nd | 5 (13) |
| * other | 1 (3) |
| **Abiraterone line** |  |
| * 1st | 24 (92) |
| * 2nd | 2 (8) |
| * 3rd | 0 (0) |
| **Enzalutamide line** |  |
| * 1st | 7 (64) |
| * 2nd | 3 (27) |
| * 3rd | 1 (9) |
| **Prior use of abiraterone for mCRPC** |  |
| * yes | 3 (27) |
| * no | 8 (73) |
| **Prior use of enzalutamide for mCRPC** |  |
| * yes | 2 (8) |
| * no | 24 (92) |